EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pattern‐Based P53 Immunohistochemistry Predicts Recurrence in Colorectal Liver Metastases Without Complete Pathologic Response After Neoadjuvant Chemotherapy

Phat Thi Hong Ho, Duy Duc Nguyen iD, Vuong Dinh Thy Hao, Giang Huong Tran, Lam Viet Trung, Thinh Van Hoang, Hoang Bac Nguyen

Cancer Reports · 2026

DOI: 10.1002/cnr2.70701 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2026. Verfasst von Phat Thi Hong Ho und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University Medical Center Ho Chi Minh City, Ho Chi Minh City, Vietnam. Hauptthemen laut MEDLINE: Liver Neoplasms, Tumor Suppressor Protein p53, Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aberrant p53 expression may have prognostic significance in colorectal cancer; however, its role in patients with colorectal liver metastases (CRLM) who receive neoadjuvant chemotherapy but do not achieve pathological complete response (pCR) remains unclear.

Aims

We evaluated whether aberrant p53 expression assessed by immunohistochemistry (IHC) predicts recurrence‐free survival (RFS) in patients with CRLM receiving neoadjuvant FOLFOXIRI followed by resection without achieving pCR. Methods and Results A prospective cohort study was conducted on 39 patients with CRLM who met the inclusion criteria. All patients received neoadjuvant chemotherapy with the FOLFOXIRI regimen. Following surgical resection of both primary colorectal tumors and liver metastases, none of the patients achieved pCR. Immunohistochemistry was performed to assess p53 expression in resected liver metastasis specimens using a pattern‐based interpretation model. RFS was analyzed using univariate and multivariate Cox proportional hazards models. Aberrant p53 expression was observed in 20 patients (51.3%). In univariate analysis, aberrant p53 expression (HR = 2.20; 95% CI: 1.02–4.71; p = 0.043), total tumor size > 6 cm (HR = 5.62; 95% CI: 2.31–13.68; p < 0.001), number of liver metastases > 4 (HR = 4.41; 95% CI: 1.59–12.26; p = 0.004), and positive surgical margin (HR = 2.62; 95% CI: 1.16–5.91; p = 0.021) were significantly associated with recurrence. In multivariate analysis, aberrant p53 expression (HR = 3.78; 95% CI: 1.56–9.15; p = 0.003) and total tumor size > 6 cm (HR = 5.23; 95% CI: 1.56–17.55; p = 0.007) remained independent prognostic factors for shorter RFS.cnr270701_RedLinePDF.

Conclusion

Aberrant p53 expression, as assessed by immunohistochemistry on post‐neoadjuvant chemotherapy specimens, is an independent prognostic factor for early recurrence in patients with CRLM who did not achieve pCR. Together with total tumor size, aberrant p53 expression may serve as a useful marker for risk stratification and personalized postoperative treatment strategies in this high‐risk patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsTumor Suppressor Protein p53Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalBiomarkers, TumorHumansFemaleMaleNeoadjuvant TherapyPathologic Complete ResponseMiddle AgedImmunohistochemistryProspective StudiesAgedPrognosisLeucovorinFluorouracilHepatectomyOrganoplatinum CompoundsChemotherapy, AdjuvantAdultDisease-Free Survival

Stichwörter der Autor:innen

colorectal liver metastasesp53recurrence‐free survival

Substanzen

Tumor Suppressor Protein p53TP53 protein, humanLeucovorinBiomarkers, TumorFluorouracilOrganoplatinum Compounds

Autor:innen und Institutionen

  • Department of Pathology, University Medical Center Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Department of Medical Oncology, Oncology Center-Cho Ray Hospital, Ho Chi Minh City, Vietnam.
  • Department of Histology, Embryology and Pathology, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Digestive Surgery Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam.
  • Department of Pathology, Cho Ray Hospital, Ho Chi Minh City, Vietnam.
  • Department of General Surgery, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.

ORCID-Profile: Duy Duc Nguyen

Zitieren

APA

Ho, P. T. H., Nguyen, D. D., Hao, V. D. T., Tran, G. H., Trung, L. V., Van Hoang, T., & Nguyen, H. B. (2026). Pattern‐Based P53 Immunohistochemistry Predicts Recurrence in Colorectal Liver Metastases Without Complete Pathologic Response After Neoadjuvant Chemotherapy. Cancer Reports. https://doi.org/10.1002/cnr2.70701

Vancouver

Ho PTH, Nguyen DD, Hao VDT, Tran GH, Trung LV, Van Hoang T, et al. Pattern‐Based P53 Immunohistochemistry Predicts Recurrence in Colorectal Liver Metastases Without Complete Pathologic Response After Neoadjuvant Chemotherapy. Cancer Reports. 2026. doi:10.1002/cnr2.70701

BibTeX
@article{Ho2026,
  author = {Ho, Phat Thi Hong and Nguyen, Duy Duc and Hao, Vuong Dinh Thy and Tran, Giang Huong and Trung, Lam Viet and Van Hoang, Thinh and Nguyen, Hoang Bac},
  title = {Pattern‐Based P53 Immunohistochemistry Predicts Recurrence in Colorectal Liver Metastases Without Complete Pathologic Response After Neoadjuvant Chemotherapy},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70701}
}
Kostenlos starten →